AB1289 HIGHER BASELINE FDG JOINT UPTAKE AT PET/CT IS ASSOCIATED WITH A HIGHER REMISSION RATE IN POLYMYALGIA RHEUMATICA: A RETROSPECTIVE 3-YEAR OBSERVATIONAL STUDY
Authors: E. Hysa, D. Camellino, C. Bernini, P. Clini, M. Bauckneht, S. Morbelli, G. Sambuceti, A. Sulli, M. Cutolo, M. A. Cimmino
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases of the elderly characterized by increased musculoskeletal and vascular uptakes of 18F-fluorodeoxyglucose (FDG) at positron emission tomography/computerized tomography (PET/CT). In contrast to GCA, where the involvement of large vessels is associated with increased disease flares and vascular complications, the prognostic significance of nuclear imaging findings in PMR is less known. <h3>Objectives:</h3> The aim of our study was to evaluate if increased baseline joint and vascular uptake of FDG could predict the clinical outcomes of patients with PMR followed-up for three years. <h3>Methods:</h3> Eighty-three patients diagnosed with PMR according to Bird et al criteria (mean age 72.2 ± 8.4, females 66.2%, disease duration, 105.4 ± 98.1 days) were included. None of the patients met the ACR 1990 classification criteria for GCA. At first visit (V0), patients underwent clinical, laboratory assessments and FDG-PET/CT; follow-up visits were performed every 6 months for a mean of 3 years. Clinical outcomes included the total number of relapses, remission rate, cumulative glucocorticoid (GC) dosage, GC discontinuation, need for methotrexate (MTX), and death. A relapse was defined as the reappearance of symptoms of PMR or the onset of GCA manifestations, accompanied by an increase of the inflammatory markers. Remission was ascertained according to two definitions: a PMR disease activity score &lt; 7 and as per Delphi-based consensus. Joint and vascular FDG uptake were visually evaluated in comparison with liver uptake and summed up to obtain the total joint score (TJS) and the total vascular score (TVS). Regression analysis was conducted using as predictors TJS, TVS, grade-2 or grade-3 large vessel vasculitis (LVV), and baseline demographic, clinical and laboratory parameters. <h3>Results:</h3> The mean TJS and TVS were, respectively, 19.3 ± 6.5 and 10.7 ± 7.6. Grade-2 LVV was present in 32 (39%) out of 83 patients with PMR and grade-3 LVV in 10 (12%). The average GC daily dosage prescribed at V0 was 15.4 ± 6.3 mg of prednisone, 19 patients (23%) were already in treatment with GC whereas 11 (13%) received MTX at V0 due to concomitant peripheral arthritis (46%), comorbidities which might have been worsened by chronic GC treatment (36%) and LVV at PET (18%). In the latter cases, MTX was prescribed soon after the results of PET/CT. At follow-up, 35% of PMR patients experienced at least one PMR flare and 10% showed at least one relapse in the form of GCA. The highest remission rate (92%) was achieved at the 24th month (Figure 1). The baseline TJS was inversely associated with PMR relapses (β = -0.22, p = 0.04, Figure 2). In the subgroup of GC-naïve PMR patients, increased TJS values were directly associated with a higher likelihood of achieving remission at 6th month (OR = 1.11, 95%CI [1.01-1.23], p = 0.02). None of these associations were influenced by the initial treatment with GC or MTX at mediation analysis (respectively, p = 0.074, p = 0.883 for PMR relapses and p = 0.21, p = 0.43 for achievement of remission at 6th month). Baseline TVS was directly but marginally associated with MTX prescription at follow-up (β = 0.08, p = 0.01) but the presence of grade-2 or 3 LVV at baseline was not significantly associated to poor prognostic outcomes at univariate analyses (all p-values &gt; 0.05). <h3>Conclusion:</h3> High FDG-PET/CT detected musculoskeletal inflammation may be a positive prognostic factor in PMR and might potentially identify phenotypes of PMR patients better responding to GC treatment. Conversely, higher TVS values might predict the need for immunosuppressive treatment. The limitation of a potential indication bias for the latter prognostic factor should be considered. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>